Abstract: A compound of the present invention comprises a triazapentalene backbone represented by the general formula 1 below as a fluorescent chromophore.

Abstract: The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives.

Abstract: A compound of the present invention comprises a triazapentalene backbone represented by the general formula 1 below as a fluorescent chromophore.

Abstract: Substituted tetraazapentalenes have two benzenoid rings and eight substitutable positions. Substitutions are made of hydrogen or C—H groups in favor of amino groups, nitro groups or nitrogen atoms. The tetraazapentalenes are synthesized through an intermediate azo, which is made from a 1:1:1 molar ratio of a nitroaniline, sodium nitrite and an amine.

Abstract: A thin film transistor comprising at least three terminals consisting of a gate electrode, a source electrode and a drain electrode; an insulating layer and an organic semiconductor layer on a substrate, which controls its electric current flowing between the source and the drain by applying a electric voltage across the gate electrode, wherein the organic semiconductor layer comprises a heterocyclic compound containing a nitrogen atom formed by condensation between five member rings each having a nitrogen atom at their condensation sites or between a five member ring and a six member ring each having a nitrogen atom at their condensation sites. The transistor became to have a fast response speed (driving speed), and further, achieved a large on/off ratio getting an enhanced performance as a transistor.

Abstract: An explosive formulation including 2,4,8,10-tetranitro-5H-pyrido[3?,2?:4,5][1,2,3]triazolo[1,2-a]benzotriazol-6-ium, inner salt and a high temperature binder is disclosed together with a process of preparing 2,4,8,10-tetranitro-5H-pyrido[3?,2?:4,5][1,2,3]triazolo[1,2-a]benzotriazol-6-ium, inner salt.

Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.

Abstract: The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.

Abstract: Compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and at least one bicyclic fused 5-5-membered aza heteroaromatic keratin dyeing compounds having a ring junction nitrogen and an N-hydroxy or N-amino group and derivatives thereof. A method for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period sufficient to develop the desired coloration.

Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Abstract: A compound represented by the following formula (I), and a silver halide color photographic light-sensitive material containing the compound as a coupler: 1

Abstract: A coupler represented by the following formula (I), and a silver halide color photographic light-sensitive material containing the coupler: 1

Abstract: A method of making a polymer having specific physiochemical properties by forming a first module having a structure which includes at least two structural diversity elements suitable to impart a desired physical property to a polymer which is made from said monomer; and reacting one or more modules to form a polymer having specific physiochemical properties. The base module can be formed by reacting a first compound having at least one structural diversity element and a first reactive group, with a second compound having at least one structural diversity element and a second reactive group, wherein the first and second groups combine by an addition reaction. Specifically, an aminimide compound, an oxazolone compound or derivatives thereof are useful as base modules in the invention.

Abstract: Nonlinear optical compounds which contain a heteroaromatic ring and may further comprise a tricyanovinyl group attached to the heteroaromatic ring.

Abstract: There are disclosed preparation and compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen or lower alkyl or taken together are a --CH.sub.2 -- group to form a cyclopropane ring.X is ##STR2## wherein R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are hydrogen or alkyl,p and q are independently either 0 or 1;R.sup.3 is alkyl, alkenyl, cycloalkyl, alkoxy, thiopyridyl, adamantyl, --NR.sup.9 R.sup.10 or --Ar--NR.sup.9 R.sup.10 whereinR.sup.9 and R.sup.10 are hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, adamantyl, aryl, benzyl, diphenylmethyl, norbornyl, or taken together with the nitrogen to form 4 to 8 atom heterocyclic group, ##STR3## optionally substituted with alkyl groups; Ar is aromaticR.sup.4 is hydrogen or methyl;Z is --O--, --NH--, --N(lower alkyl), --S--, --SO--, --SO.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, CO, CO.sub.2, O.sub.2 C, --N.dbd.N--, --CH.dbd.N--, or --N.dbd.CH--,and n and m are 0, 1 or 2.

Abstract: Compounds useful as polymer stabilizers which are polymerizable into condensation polymer systems are disclosed and claimed. A particularly preferred embodiment is 1-(3'-(benzotriazol-2"-yl)-4'-hydroxyphenyl)-1,1-bis(4-hydroxyphenyl)ethan e.

Abstract: Nitro-substituted heterocyclic compounds of the formula (I) ##STR1## wherein R is hydrogen or alkyl, Z is an optionally substituted aryl or optionally substituted heterocyclic group containing at least one atom selected from N, O and S,A is optionally substituted ethylene or optionally substituted trimethylene, andB stands for 2 or 3 members of a heterocyclic ring which is formed, together with the adjacent C-atom and N-atom and at least one of said members may represent a hetero atom and may be optionally substituted, provided that when B stands for 3 members, two of which are carbon atoms and the other one is a nitrogen atom which is located in the middle of the three members, then at least one of said two carbon atoms must be substituted by a keto group. Such compounds being useful as insecticides.

Abstract: New derivatives of penem and pharmaceutically acceptable salt thereof are herein disclosed; these compounds being useful as an antibacterial agent which has an extremely wide antibacterial spectrum, exhibits a high sensitivity to bacteria resistant to conventional penicillins and cephalosporing antibiotics and is excellent in its physico-chemical stability, solubility to water and biological stability, in particular, stability to decomposition by enzyme such as dehydropeptidase I in kidney, .beta.-lactamase; these derivatives of penem being able to be prepared by reacting 2-substituted sulfinyl derivative of penem with a thiol compound and then optionally removing protective group(s) and further alkylating the reaction product or vice versa.

Abstract: A 1,7-diacetylpyrazolotriazole was prepared by acid catalyzed acetylation of 6-methyl-3-[3-(4-nitrophenyl)propyl]-1H-pyrazolo[5,1-C]-1,2,4-triazole. Hydrolysis gave the 7-acetylpyrazolotriazole. Oxidation converted the 7-acetylpyrazolotriazole to a 7-acetoxypyrazolotriazole.

Abstract: There are described new halocyclopropyl compounds of the general formula I ##STR1## in which R.sub.1, R.sub.2 and R.sub.3, independently of each other, are hydrogen or C.sub.1-4 -alkyl,X is hydrogen or halogen,Y is halogen,n is 0, 1, 2 or 3,U and V are hydrogen or halogen, andW is a heterocyclic group of formula ##STR2## in which T is halogen, C.sub.1-4 -alkyl, C.sub.1-4 -haloalkyl, CN or OR.sub.9Q is CH or N,Z is O or S,R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each a straight, branched or cyclic C.sub.1-7 -alkyl group optionally substituted by up to six halogen atoms, orR.sub.4 and R.sub.5, can also together form a 4 to 7 membered ring that is saturated or unsaturated and can contain further hetero atoms, such as O, S or N, and can optionally be substituted by one to three methyl groups or one to six halogen atoms, andR.sub.9 is hydrogen, C.sub.1-4 -alkyl or C.sub.1-4 -haloalkyl,processes for their preparation and their use as herbicide with high selectivity.

Abstract: Tetranitrodibenzo-1,3a,4,6a-tetrazapentalene is prepared from diaminobenzene by reacting diaminobenzene and lead dioxide in ethylacetate to produce diaminoazobenzene, isolating the product by silica-gel elution, reacting diaminoazobenzene with an inorganic azide in a dilute aqueous nitrous acid solution at a temperature not in excess of 10.degree. C. to produce diazidoazobenzene, isolating the product, heating diazidoazobenzene slowly to about 190.degree. C. until nitrogen stops evolving to form dibenzotetrazapentalene, isolating the product, nitrating dibenzotetrazapentalene with concentrated sulfuric acid and forming nitric at a temperature not in excess of about 65.degree. C. to product tetranitrodibenzo-1,3a,4,6a-tetrazapentalene.

Abstract: Tricyclic nitrogenous compounds having strong plant growth regulating properties are disclosed. The compounds display the general formula ##STR1## wherein A is one of several nitrogen-containing radicals, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from various recited aliphatic, aryl, araliphatic and heterocyclic groups. R.sup.3 and R.sup.4 may also together form one of a number of nitrogen, sulfur and oxygen containing radicals. These compounds have a variety of uses, including the reduction of plant growth height without harm to the plant.